{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:54:31Z","timestamp":1793066071275,"version":"4.5.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated virus (AAV) gene therapies are highly promising, such as the onasemnogene abeparvovec (Zolgensma) in spinal muscle atrophy (SMA). We report the first case of fatal systemic thrombotic microangiopathy (TMA) following onasemnogene abeparvovec in a 6-month-old child with SMA type 1, carrying a potential genetic predisposition in the complement factor I gene. Other cases of TMA have recently been reported after onasemnogene abeparvovec and after AAV9 minidystrophin therapy in Duchenne muscular dystrophy. The risk-benefit ratio of this therapy must therefore be assessed. Early recognition of TMA and targeted immunotherapy are fundamental to ensure the safety of patients treated with AAV gene therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006419","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T16:24:38Z","timestamp":1652891078000},"page":"4266-4270","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":169,"title":["Fatal thrombotic microangiopathy case following adeno-associated viral\n                    <i>SMN<\/i>\n                    gene therapy"],"prefix":"10.1182","volume":"6","author":[{"given":"Julia","family":"Guillou","sequence":"first","affiliation":[{"name":"1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-6352","authenticated-orcid":false,"given":"Alice","family":"de Pellegars","sequence":"additional","affiliation":[{"name":"2CHU Angers, F\u00e9d\u00e9ration de P\u00e9diatrie, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Porcheret","sequence":"additional","affiliation":[{"name":"1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-8528","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[{"name":"3Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges Pompidou, Service d'Immunologie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Allain-Launay","sequence":"additional","affiliation":[{"name":"1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Debord","sequence":"additional","affiliation":[{"name":"4CHU Nantes, Laboratoire d\u2019h\u00e9matologie, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Denis","sequence":"additional","affiliation":[{"name":"5CHU Nantes, Paediatric Intensive Care Unit, Nantes, France;"},{"name":"6Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale (INSERM), l'Institut du Thorax, Universit\u00e9 de Nantes, Centre National de la Recherche Scientifique (CNRS) , Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-3571","authenticated-orcid":false,"given":"Yann","family":"P\u00e9r\u00e9on","sequence":"additional","affiliation":[{"name":"7CHU Nantes, Reference Centre for Neuromuscular Disorders, Atlantique - Occitanie - Cara\u00efbes (AOC) , Filnemus, Euro-NMD, University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Barn\u00e9rias","sequence":"additional","affiliation":[{"name":"8Reference Center for Neuromuscular Disorders, Filnemus, EuroNMD, Assistance Publique-H\u00f4pitaux de Paris (APHP) Necker Enfants Malades Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[{"name":"8Reference Center for Neuromuscular Disorders, Filnemus, EuroNMD, Assistance Publique-H\u00f4pitaux de Paris (APHP) Necker Enfants Malades Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Roussey","sequence":"additional","affiliation":[{"name":"1Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-8748","authenticated-orcid":false,"given":"Sandra","family":"Mercier","sequence":"additional","affiliation":[{"name":"6Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale (INSERM), l'Institut du Thorax, Universit\u00e9 de Nantes, Centre National de la Recherche Scientifique (CNRS) , Nantes, France"},{"name":"9CHU Nantes, Service de G\u00e9n\u00e9tique M\u00e9dicale, Centre de R\u00e9f\u00e9rence des Maladies Neuromusculaires AOC, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"1","key":"2022072215253202800_B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"2022072215253202800_B2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"2022072215253202800_B3","author":"Chand"},{"issue":"10","key":"2022072215253202800_B4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"issue":"4","key":"2022072215253202800_B5","first-page":"284","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"20","author":"Chand","year":"2021","journal-title":"J Pediatr."},{"key":"2022072215253202800_B6","author":"Food and Drug Administration. Highlights of Prescribing Information"},{"issue":"1","key":"2022072215253202800_B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"2022072215253202800_B8","author":"EMA Direct Healthcare Professional Communication"},{"issue":"12","key":"2022072215253202800_B9","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","article-title":"Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation","volume":"27","author":"Cayci","year":"2012","journal-title":"Pediatr Nephrol."},{"issue":"6","key":"2022072215253202800_B10","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet."},{"issue":"13","key":"2022072215253202800_B11","first-page":"3861","article-title":"Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels","volume":"24","author":"Kavanagh","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"14","key":"2022072215253202800_B12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/hmg\/ddaa114","article-title":"Effect of rare coding variants in the CFI gene on factor I expression levels","volume":"29","author":"de Jong","year":"2020","journal-title":"Hum Mol Genet."},{"issue":"8","key":"2022072215253202800_B13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood."},{"key":"2022072215253202800_B14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","author":"Mendell","year":"2021","journal-title":"Mol Ther."},{"key":"2022072215253202800_B15","author":"Rocket Pharmaceuticals announces positive updates from phase 1 clinical trial of RP-A501 in Danon disease"},{"issue":"6","key":"2022072215253202800_B16","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"2022072215253202800_B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2019-128090","article-title":"Soluble C5b-9 as a prognostic biomarker for thrombotic microangiopathy at the onset of graft-versus-host disease","volume":"134","author":"Li","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4266\/1909514\/advancesadv2021006419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4266\/1909514\/advancesadv2021006419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T11:25:50Z","timestamp":1658489150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4266\/485289\/Fatal-thrombotic-microangiopathy-case-following"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006419","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}